Haleon invests in India manufacturing

Haleon, a British consumer health company, announced a strategic investment of approximately ₹2,000 crore (£175 million) to establish its first manufacturing facility in India. The greenfield plant will be located in Pithampur, India — Madhya Pradesh, and is expected to be operational by 2029-30. This facility will primarily focus on oral care products, including its flagship brand Sensodyne, and will serve both the domestic Indian market and export to other Asian markets. The investment aligns with India's 'Make in India' initiative, aiming to strengthen the supply chain, reduce reliance on imports, and create up to 500 direct jobs. Haleon's CEO, John McNamara, highlighted India's significance as a key strategic market and a major driver of the company's long-term growth, with an ambition to reach 300 million additional consumers in India by 2030. The company also plans to accelerate investments in distribution, research, and consumer education, while exploring inorganic growth opportunities through bolt-on acquisitions in high-growth categories and markets like India.